Zaans Medisch Centrum Stichting

At Zaans Medisch Centrum Stichting, the clinical trial portfolio spans cardiology and cancer research, with studies focused on improving care for atherosclerotic heart and blood vessel disease, atrial fibrillation, breast neoplasms, and Diffuse Large B-Cell Lymphoma. These trials are designed to test new treatment options, compare them with standard care, and assess whether they can better reduce disease risk or improve outcomes.

• Research on cardiovascular disease aims to lower the risk of major heart and vascular events and prevent stroke in people with atrial fibrillation.
• Oncology studies include breast cancer and DLBCL, with a focus on strengthening cancer control and extending time without disease progression.
• Trials are evaluating whether newer therapies can offer better effectiveness than established treatments in both heart disease and cancer.

The site contributes to a broad mix of preventive and treatment-focused research, reflecting a strong interest in both cardiovascular outcomes and oncology care.

Clinical research in this area centers on cardiology, especially the prevention of stroke and systemic embolism in people with atrial fibrillation. The studies are intended to determine whether newer anticoagulation approaches can improve protection while maintaining a favorable safety profile.

• Focus on reducing the chance of stroke and other clot-related complications.
• Comparison of emerging treatment strategies with established care for atrial fibrillation.
• Evaluation of overall balance between benefit and bleeding risk in patients at risk for thromboembolic events.

This work supports better decision-making for patients who need long-term prevention of serious cardiovascular complications.

Another key research theme at the site is atherosclerotic cardiovascular disease, where trials are assessing whether new lipid-related treatments can further reduce the risk of major events such as heart attack, stroke, and cardiovascular death. The goal is to improve outcomes for people whose current treatment is not enough.

• Studies target patients with persistent cardiovascular risk despite standard therapy.
• Research is aimed at preventing major adverse heart and blood vessel events.
• Investigations compare newer options with usual care to see if protection can be improved.

These trials reflect a practical effort to strengthen long-term prevention in cardiology.

The oncology studies at Zaans Medisch Centrum Stichting include research in early breast cancer and Diffuse Large B-Cell Lymphoma. These trials are exploring whether adding newer therapies to standard cancer treatment can improve disease control and extend the time patients remain free from progression or recurrence.

• Research in breast neoplasms is centered on lowering recurrence risk after initial treatment.
• DLBCL studies are evaluating whether treatment combinations can improve progression-free survival.
• The overall aim is to test more effective cancer strategies while keeping standard treatment as the foundation.

This oncology work highlights a focus on both solid tumors and blood cancers, with the aim of improving patient outcomes through better treatment combinations.